Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 55

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 55
---
 would beneficially own in excess of 4.99% (or, upon election of the holder prior to the issuance of any warrants, up to
9.99%) of the number of shares of our Depositary Shares outstanding immediately after giving effect to the exercise, as such percentage
ownership is determined in accordance with the terms of the warrants. However, any holder may increase or decrease such percentage to
any other percentage not in excess of 9.99%, upon at least 61 days’ prior notice from the holder to us with respect to any increase
in such percentage.

Transferability.
Subject to applicable laws, the Series L Warrants and Pre-Funded Warrants may be offered for sale, sold, transferred or assigned without
our consent.

Exchange Listing.
We do not intend to list the Series L Warrants or the Pre-Funded Warrants offered in this offering on any securities exchange or other
trading market. Without an active trading market, the liquidity of these securities will be limited.

Rights as a Shareholder.
Except as otherwise provided in the Series L Warrants or the Pre-Funded Warrants or by virtue of such holder’s ownership of our
Depositary Shares, the holder of a Series L Warrant or Pre-Funded Warrant does not have the rights or privileges of a holder of our Depositary
Shares, including any voting rights, until the issuance of Depositary Shares upon exercise of the warrant. Holders of Pre-Funded Warrants
and Series L Warrants have the right to participate in dividends and certain distributions as specified in the warrant.

Fractional Shares.
No fractional Depository Shares will be issued upon the exercise of the Pre-Funded Warrants or the Series L Warrants. Rather, the number
of Depository Shares to be issued upon the exercise of the Pre-Funded Warrants will be rounded up to the nearest whole number. The number
of Depository Shares underlying the Series L Warrants to be issued will, at our election, either be rounded up to the nearest whole number
or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price.

Fundamental Transactions.
In the event of a fundamental transaction, as described in the Series L Warrants and the Pre-Funded Warrants and generally including,
with certain exceptions, any reorganization, recapitalization or reclassification of our Depositary Shares, the sale, transfer or other
disposition of all or substantially all of our properties or assets, our